Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization.
10.5653/cerm.2013.40.3.131
- Author:
Su Kyoung KWON
1
;
Chung Hoon KIM
;
Kyung Hee LEE
;
Il Kyung JEON
;
Jun Woo AHN
;
Sung Hoon KIM
;
Hee Dong CHAE
;
Byung Moon KANG
Author Information
1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. chnkim@amc.seoul.kr
- Publication Type:In Vitro ; Original Article ; Randomized Controlled Trial
- Keywords:
Luteal progesterone supplementation;
Gonadotropin-releasing hormone antagonist;
Addition of estradiol;
In vitro fertilization;
Intracytoplasmic sperm injection
- MeSH:
Aged;
Embryo Implantation;
Estradiol;
Female;
Fertilization in Vitro;
Follicle Stimulating Hormone, Human;
Gonadotropin-Releasing Hormone;
Humans;
Incidence;
Ovulation Induction;
Pregnancy;
Pregnancy Outcome;
Pregnancy Rate;
Progesterone;
Prospective Studies;
Sperm Injections, Intracytoplasmic;
Uterine Hemorrhage
- From:Clinical and Experimental Reproductive Medicine
2013;40(3):131-134
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the effect of the addition of estradiol to luteal progesterone supplementation in GnRH antagonist cycles for infertile patients undergoing IVF/ICSI. METHODS: One hundred and ten infertile patients, aged 28 to 39 years, were recruited for this prospective randomized study. They were randomly assigned to receive vaginal progesterone gel (Crinone) along with 4 mg estradiol valerate (group 1, n=55) or only Crinone (group 2, n=55) for luteal support. A GnRH antagonist multiple dose protocol using recombinant human FSH was used for controlled ovarian stimulation (COS) in all of the subjects. The COS results and pregnancy outcomes of the two groups were compared. RESULTS: Group 1 and 2 were comparable with respect to the patient characteristics. The COS and IVF results were also comparable between the two groups. There were no differences in the clinical pregnancy rate (PR) and multiple PR between the two groups. However, the embryo implantation rate were significantly higher in group 1 than that in group 2 (22.2% vs. 13.3%, p=0.035). The incidence of luteal vaginal bleeding (LVB) was significantly lower in group 1 (7.4% vs. 27.8%, p=0.010). CONCLUSION: The addition of estradiol to luteal progesterone supplementation in GnRH antagonist cycles reduces the incidence of LVB and increases the embryo implantation rate in infertile patients undergoing IVF/ICSI.
